Avantor Investor Day Presentation Deck

Segment to Avantor walk Revenue Adj. Operating Income Depreciation Adj. EBITDA LABORATORY SOLUTIONS ~$4.7B ~$0.7B -15% BIOSCIENCE PRODUCTION -$2.3B ~$0.6B ~26% CORPORATE 2023E financials based on midpoint of FY 2023 guidance, as of Q3 2023 earnings call. Adjusted Operating Income generally includes non-GAAP adjustments and excludes amortization. Segment financials based on management estimates for FY2023. Effective date for the new segment structure is 1/1/24. Segment profitability metric transitioning to adjusted operating income $0.0B ~($0.1B) AVANTOR ~$7.0B ~$1.2B ~17% ~$0.1B ~$1.3B ~19% Navantor™ 90

View entire presentation